Al-Ramahi, Joe S.
Shahzad, Moazzam http://orcid.org/0000-0002-9609-6160
Nguyen, Andrea http://orcid.org/0000-0002-9439-3903
Li, Kevin
Amin, Muhammad Kashif http://orcid.org/0000-0002-4052-7339
Ahmed, Nausheen http://orcid.org/0000-0003-4336-4982
Lutfi, Forat
DeJarnette, Shaun
Chaudhary, Sibgha Gull
Bansal, Rajat
Abdelhakim, Haitham
Shune, Leyla
Abdallah, Al-Ola
Singh, Anurag K. http://orcid.org/0000-0003-1114-9508
Abhyankar, Sunil H. http://orcid.org/0000-0002-8578-1226
McGuirk, Joseph P. http://orcid.org/0000-0002-0539-4796
Mushtaq, Muhammad Umair http://orcid.org/0000-0001-8122-0563
Article History
Received: 23 June 2023
Revised: 26 September 2023
Accepted: 5 October 2023
First Online: 13 October 2023
Competing interests
: SHA has speaking, consulting, and advisory roles, and research funding from Incyte and Therakos. JPM has speaking, consulting, and advisory role in Kite, Juno Therapeutics, Allovir, Magenta Therapeutics, EcoR1 Capital, and has research funding from Novartis, Fresenius Biotech, Astellas Pharma, Bellicum Pharmaceuticals, Gamida Cell, Pluristem Therapeutics, Kite and AlloVir. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.